TY - JOUR
T1 - Cardiovascular involvement in patients affected by multiple myeloma: a comprehensive review of recent advances
AU - Camilli, Massimiliano
AU - La Vecchia, Giulia
AU - Lillo, Rosa
AU - Iannaccone, Giulia
AU - Lamendola, Priscilla
AU - Montone, Rocco Antonio
AU - Hohaus, Stefan
AU - Aspromonte, Nadia
AU - Massetti, Massimo
AU - Lanza, Gaetano Antonio
AU - Crea, Filippo
AU - Graziani, Francesca
AU - Lombardo, Antonella
PY - 2021
Y1 - 2021
N2 - Introduction: Multiple Myeloma (MM) is hematological neoplasia originating from plasma cells, which accounts for almost 1% of all oncologic malignancies. The median age of patients at diagnosis is about 65 years old and over. In this age group, cardiovascular (CV) diseases often co-exist, increasing the risk of adverse events related to MM treatment. A comprehensive search on the main educational platforms was performed and high-quality original articles and reviews were included. Areas Covered: Patients affected by MM are at risk for heart failure, uncontrolled systemic hypertension, accelerated ischemic heart disease, arterial/venous thromboembolism, and arrhythmias. These complications may be due to the effects of chemotherapy on the CV system, which may play on preexisting risk factors, and amyloid deposition at cardiac level. Expert Opinion: This review provides an updated overview of the spectrum of CV diseases that may affect MM patients, highlighting possible treatment strategies according to the latest recommendations. Cooperation between onco-hematologist and cardiologist is crucial in managing this population, in particular for adequate risk assessment, early diagnosis of CV complications, and proper treatment.
AB - Introduction: Multiple Myeloma (MM) is hematological neoplasia originating from plasma cells, which accounts for almost 1% of all oncologic malignancies. The median age of patients at diagnosis is about 65 years old and over. In this age group, cardiovascular (CV) diseases often co-exist, increasing the risk of adverse events related to MM treatment. A comprehensive search on the main educational platforms was performed and high-quality original articles and reviews were included. Areas Covered: Patients affected by MM are at risk for heart failure, uncontrolled systemic hypertension, accelerated ischemic heart disease, arterial/venous thromboembolism, and arrhythmias. These complications may be due to the effects of chemotherapy on the CV system, which may play on preexisting risk factors, and amyloid deposition at cardiac level. Expert Opinion: This review provides an updated overview of the spectrum of CV diseases that may affect MM patients, highlighting possible treatment strategies according to the latest recommendations. Cooperation between onco-hematologist and cardiologist is crucial in managing this population, in particular for adequate risk assessment, early diagnosis of CV complications, and proper treatment.
KW - Aged
KW - Arrhythmias, Cardiac
KW - Cardiovascular Diseases
KW - Humans
KW - Hypertension
KW - Multiple Myeloma
KW - Risk Factors
KW - amyloidosis
KW - cardio-oncology
KW - cardiotoxicity
KW - cardiovascular complications
KW - Aged
KW - Arrhythmias, Cardiac
KW - Cardiovascular Diseases
KW - Humans
KW - Hypertension
KW - Multiple Myeloma
KW - Risk Factors
KW - amyloidosis
KW - cardio-oncology
KW - cardiotoxicity
KW - cardiovascular complications
UR - http://hdl.handle.net/10807/204979
U2 - 10.1080/17474086.2021.2003704
DO - 10.1080/17474086.2021.2003704
M3 - Article
SN - 1747-4086
VL - 14
SP - 1115
EP - 1128
JO - Expert Review of Hematology
JF - Expert Review of Hematology
ER -